Sumitomo Pharma Statistics

Total Valuation

Sumitomo Pharma has a market cap or net worth of 2.33 billion. The enterprise value is 4.24 billion.

Market Cap	2.33B
Enterprise Value	4.24B

Important Dates

The last earnings date was Tuesday, May 13, 2025.

Earnings Date	May 13, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	397.29M
Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.00%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	180.16M

Valuation Ratios

The trailing PE ratio is 14.78.

PE Ratio	14.78
Forward PE	n/a
PS Ratio	0.88
PB Ratio	2.06
P/TBV Ratio	n/a
P/FCF Ratio	43.65
P/OCF Ratio	21.17
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 16.64, with an EV/FCF ratio of 79.39.

EV / Earnings	26.88
EV / Sales	1.57
EV / EBITDA	16.64
EV / EBIT	51.75
EV / FCF	79.39

Financial Position

The company has a current ratio of 1.05, with a Debt / Equity ratio of 1.80.

Current Ratio	1.05
Quick Ratio	0.42
Debt / Equity	1.80
Debt / EBITDA	7.92
Debt / FCF	38.17
Interest Coverage	0.96

Financial Efficiency

Return on equity (ROE) is 14.52% and return on invested capital (ROIC) is 1.55%.

Return on Equity (ROE)	14.52%
Return on Assets (ROA)	0.99%
Return on Invested Capital (ROIC)	1.55%
Return on Capital Employed (ROCE)	2.59%
Revenue Per Employee	534,810
Profits Per Employee	31,692
Employee Count	4,980
Asset Turnover	0.48
Inventory Turnover	1.46

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +141.85% in the last 52 weeks. The beta is 0.54, so Sumitomo Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.54
52-Week Price Change	+141.85%
50-Day Moving Average	3.57
200-Day Moving Average	10.91
Relative Strength Index (RSI)	69.25
Average Volume (20 Days)	2,932

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Sumitomo Pharma had revenue of 2.66 billion and earned 157.83 million in profits. Earnings per share was 0.40.

Revenue	2.66B
Gross Profit	1.64B
Operating Income	86.97M
Pretax Income	117.60M
Net Income	157.83M
EBITDA	257.67M
EBIT	86.97M
Earnings Per Share (EPS)	0.40

Full Income Statement

Balance Sheet

The company has 154.37 million in cash and 2.04 billion in debt, giving a net cash position of -1.89 billion.

Cash & Cash Equivalents	154.37M
Total Debt	2.04B
Net Cash	-1.89B
Net Cash Per Share	n/a
Equity (Book Value)	1.13B
Book Value Per Share	2.85
Working Capital	83.91M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 110.19 million and capital expenditures -56.75 million, giving a free cash flow of 53.44 million.

Operating Cash Flow	110.19M
Capital Expenditures	-56.75M
Free Cash Flow	53.44M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 61.53%, with operating and profit margins of 3.27% and 5.93%.

Gross Margin	61.53%
Operating Margin	3.27%
Pretax Margin	4.42%
Profit Margin	5.93%
EBITDA Margin	9.67%
EBIT Margin	3.27%
FCF Margin	2.01%

Dividends & Yields

Sumitomo Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	0.01%
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	6.77%
FCF Yield	2.29%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Sumitomo Pharma has an Altman Z-Score of 0.93. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.93
Piotroski F-Score	n/a